Biernacki et al. demonstrated that the peptide REEMVEHEL is present on HLA-B*40:01+, activating highly specific CD8+ T-cell clones able to recognize and kill AML cells in vitro and in vivo, making it a potential target for CAR T-cell therapy [73]. This evidence concerns the gene CD8A and acute myeloid leukemia.